Brefeldin A

Catalog No.S7046

Brefeldin A  Chemical Structure

Molecular Weight(MW): 280.36

Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis.

Size Price Stock Quantity  
In DMSO USD 80 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective ATPase Inhibitors

Biological Activity

Description Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis.
Targets
ATPase (HCT 116) [1]
0.2 μM
In vitro

Brefeldin A is a fungal metabolite and blocks the forward transport between the endoplasmic reticulum and Golgi apparatus, Brefeldin A causes an impaired distribution of the membrane proteins. When HCT 116 human colon cancer cell is treated with Brefeldin A, morphological changes indicating cell differentiation are observed. Brefeldin A exerts its cytotoxic effects mainly by inducing differentiation and apoptosis in tumor cells. [1] The treatment of the strips with 20 μg/mL Brefeldin A for 6 hours completely abolishes the relaxation induced by bradykinin in the presence of 10mM indomethacin and 30 μM L-NOARG. The treatment with 20 μg/mL Brefeldin A substantially abolishes the bradykinin-induced decreases in [Ca2+]i and tension in the range of concentrations between 1 nM and 1 mM. Brefeldin A has no effect on the [Ca2+]i elevation in endothelial cells induced by bradykinin or substance P. [2] Addition of the fungal metabolite Brefeldin A does not affect the spontaneous phospholipid-dependent GTPS binding to myr-rARF1 but totally abolishs the retinal isotonic extract (RIE)-catalyzed exchange, with half-maximal inhibition at 2 μM Brefeldin A. Brefeldin A prevents a wide variety of membrane traffic pathways. Brefeldin A inhibits an ADP-ribosylation factor-specific guanine nucleotide exchange activity present in Golgi membranes or in brain cytosol. The complete prevention by Brefeldin A strongly suggests that the retinal extract contains an ARF-specific guanine nucleotide exchange factor. Retinal isotonic extract (RIE)-catalyzed GTPS release from both ADP-ribosylation factors (ARFs) is only partly inhibited by Brefeldin A, even at 300 μM. [3] Brefeldin A induces fusion of the Golgi apparatus with the ER. Brefeldin A abolishes the inhibitory effect of the CERT inhibitor HPA-12. Brefeldin A treatment, which induces fusion of the Golgi apparatus and the ER, rescues the limonoid-induced prevention of sphingomyelin biosynthesis. BFA treatment of CHO cells causes a 2 to 3 fold increase in sphingomyelin synthesis. [4] Apart from B-CLL cells, Brefeldin A reportedly causes apoptosis in multiple myeloma (U266, NCI-H929), Jurkat, HeLa, leukaemia (HL60, K562, BJAB), colon (HT-29) and prostate, as well as adenoid cystic sarcoma cells. The administration of 25 ng/mL of Brefeldin A completely blocks growth of HF4.9 and HF28RA cells, whereas higher Brefeldin A doses (75 ng/mL) are required to achieve the same effect in HF1A3 cells. Cell proliferation is inhibited within 24 hours in a dose-dependent manner and, depending on the cell line, almost complete cessation of 3H-thymdine incorporation is observed at 50-75 ng/mL of Brefeldin A (26%, 76%, 87% inhibition at 50 ng/ml and 75%, 87%, 92% inhibition at 75 ng/mL for HF1A3, HF4.9 and HF28RA cells respectively. Brefeldin A-induced cell killing is in a dose-dependent manner using YO-PRO 1/PI assay. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PC12 NFXheYpHfW6ldHnvckBCe3OjeR?= MoPYNkDPxE1? M3q3blEhcA>? NVTZNFJ5cW6qaXLpeJMhfGinIFytSG9RSSBqMkFCpO69VSlvaX7keYNm\CC2cnHud4lmdnRiRWLLNU8zKHCqb4PwbI9zgWyjdHnvcuKh M3e0PVI3OzZ|MUmx
C2C12 NEDjT|dHfW6ldHnvckBCe3OjeR?= MXyxxsDPxGdxbXy= M1ewdlHDqGh? M2LWNYFjd2yrc3jld{BkgXSxa3nu[UBz\WynYYPlJIZzd21iQ{LDNVIhdXmxdIXi[ZM> MoDoNlYzQTF{N{m=
MEFs WT NX;pZlQzTnWwY4Tpc44hSXO|YYm= MY[1xsDPxE1? NWHGfoRZOjBibXnu MV7jZZV{\XNicnXzbYRmdnRiZX76fY1meyC|dXPoJIF{KE6DR2StS2ZRNCC2bzDkbYZnfXOnIHLhZ4shfG9idHjlJGVT M{CxTFI3OTl4MEKz
MEFs VAMP7 KO M{TwOWZ2dmO2aX;uJGF{e2G7 MXq1xsDPxE1? MXuyNEBucW5? M1zxVYNifXOnczDy[ZNq\GWwdDDlcpp6dWW|IIP1Z4gh[XNiTlHHWE1ITlBuIITvJIRq\m[3c3WgZoFkcyC2bzD0bIUhTVJ? M3z3PVI3OTl4MEKz
SMCs NGTOclNHfW6ldHnvckBCe3OjeR?= NHPVSmcyOMLiwsXnM41t MYWwMVEzKGh? MoTjSG1UVw>? NF;pS45{cG:5czDhJJRz\W6mIITve4Fz\HNiYTDobYdp\XJiY3;uZ4VvfHKjdHnvckBw\iC2aHWgSXIwW1JibnX0e49zcyCrbjD0bIUheGW{aX71Z4xm[XJiYYLlZeKh MUGyOlE4OjB6MB?=
SMCs MVTGeY5kfGmxbjDBd5NigQ>? MlXhNVDDqML3Zz;tcC=> Mli0NE0yOiCq NXfzPGExTE2VTx?= NFO3bW5k[XW|ZYOgZUB1emGwc3nlcpQhS2F{K9MgdoVt\WG|ZTDmdo9uKHSqZTDFVk9UWsLi NIjJfoMzPjF5MkC4NC=>
HEMC-1 M3P6NGZ2dmO2aX;uJGF{e2G7 NWrK[JF5OC5zwrFCuYcwdWx? MVeyOOKhcA>? MV3jZZV{\XNiYTDobYdp\XJiaX7obYJqfG:{eTDl[oZm[3Rib36g[Zhw[3m2b4Ppd{B1cGGwIH7vZ49l[XqxbHW= MVqyOVk4Ojd3OR?=
HUVEC MniySpVv[3Srb36gRZN{[Xl? NITlenoyOMLizszN NWXRS|dQOcLiaB?= MYPEUXNQ NYnDfIM4[WKxbHnzbIV{KGi7cH;4bYEucW6mdXPl[EBz\WynYYPlJI9nKEGWUDDmdo9uKGGyaXPhcEBidmRiYnHzc4xifGW{YXygd5Vz\mGlZYO= MV[yOVk2Pjl6OB?=
HUVEC MmPTSpVv[3Srb36gRZN{[Xl? NH\Ye3cyOMLizszN NEmxV4EyyqCq NWPwVIczTE2VTx?= MYXpcoNz\WG|ZYRCpJRp\SCwdX3i[ZIh[W6mIHnueIVve2m2eTDv[kBndHWxcnXzZ4VvfCCjcnXhd{Bme3CnY3nhcIx6KGmwIIDldolvfWOuZXHyJJNx[WOn NHrUfGozPTl3Nkm4PC=>
Caco-2 MYHGeY5kfGmxbjDBd5NigQ>? MofMNk42KM7:TR?= NHH2R2E{OCCvaX6= M3;zfYF1fGWwdXH0[ZMhfGinIGTHSk3PujFvbXXkbYF1\WRiaX7jdoVie2ViaX6gV2VTXCCodX7jeIlwdg>? MYGyOVk2PDl|MR?=
NRK NWTiTXRQTnWwY4Tpc44hSXO|YYm= NWLIXXRJOjBy4pEFcocwdWx? MYe05qCGcA>? M4PrZmROW09? NIrlV3dz\XOldXXzJI1qfG:2aXOgdJJw\3Knc4Ppc44> Moj4NlU6PDh3OE[=
HeLa MnfJSpVv[3Srb36gRZN{[Xl? NGP5PFEzODEkgJXu[{9udA>? NGW3fFg{KGh? M3\RWGROW09? NGPHZ|lqdmS3Y3XzJJRp\SCjcoTp[olkcWGuIHLy[YFsNXWyIH;mJJRp\SCJb3znbUBkd22ybHX4 NIP1Ro8zPTl2OEW4Oi=>
COS MYLGeY5kfGmxbjDBd5NigQ>? M{WzcVEh|rypL33s Mk\vN{Bp MX\jc41xdGW2ZXz5JIRqe3CncoPld{B1cGViQWCtNUB{cWewYX|CpC=> M3zmZlI2QTF3OUCw
DF1  MWHGeY5kfGmxbjDBd5NigQ>? NHLwbJIyyqEQvF5CpC=> NGrWUIU1QCCq NYPFUHNyTE2VTx?= MXjkbZNx\XK|ZYRCpJRp\SCneH;n[Y5wfXNiQ2PHZYxPSWOWMjDwdo91\Wmw MY[yOVgxPzB3NB?=
nHDFs  M2\4eGZ2dmO2aX;uJGF{e2G7 MlO2NeKh|ryPwrC= M4\LWVLDqGh? NX3Icnd1eHKndnXueJMhfGinIHHzd4Vu[my7IH;mJIN6fG:|b3zpZ{Bkd2G2IIDyc5RmcW6|IH;ueI8hT2:uZ3mgcYVu[nKjbnXz M{jhdFI2Pzd{NkG2
FRT  NEe0VZFHfW6ldHnvckBCe3OjeR?= NVn5VpF1PSEQvHevcYw> Ml62NuKhcA>? NGHEPI5jdG:la4OgeJJi\m[rY3vpcochfGi{b4XnbEB1cGViR3;s[4kh[2:vcHzlfEBjgSCrbnjpZol1cW6pIFXSMZRwNUexbHfpJJRz[W6|cH;yeC=> NWS5UIF1OjV5NkexNVU>
FRT  MlK3SpVv[3Srb36gRZN{[Xl? MUS1JO69\y:vbB?= NEHYeo4zyqCq NX\tcVYxeHKndnXueJMhfGinIHnuZ5Jm[XOnIHnuJINt\WG4ZXSg{tEhe3WkdX7peJMhf2inbjDbUoEsZWoEoIfhd{Bz\WS3Y3Xk MXqyOVc3PzFzNR?=
HepG2  NVzRcG1kTnWwY4Tpc44hSXO|YYm= NIDJN4Yy6oDLwsXNxsA> NWD3WlhWOjRiaB?= MUjEUXNQ MnP2[IVkemWjc3XzJJRp\SCuZY\lcEBw\iCSWGKgcXJPSQ>? M2C2dFI2PjF4NUm3
SMCs NH;YXmZHfW6ldHnvckBCe3OjeR?= NE\xO2sy|rypL33M MofFN{Bp NUWzSFlK[WOldX31cIF1\XNiQ17QXVIheHKxdHXpckBqdiC2aHWgSXIh[2:vcHHyeI1mdnRiYX7kJI5wKGyxbnfldkBkdy2ub3PhcIl7\WRid3n0bEB1cGViR3;s[4khdWG{a3XyxsA> M3fBNFI2PTh7NEK1
OB-6 MX3BdI9xfG:|aYOgRZN{[Xl? NY\Ldld2Oi55wrFOwG0> M32x[|Q5KGh? NVjwOI44cW6mdXPld{BieG:ydH;zbZM> MXGyOVU{OjR6MB?=
iPSC-CMs  MljWSpVv[3Srb36gRZN{[Xl? MWq1NFAhdmdxbXy= MoXnOFghcA>? NEjwU3VqdmO{ZXHz[ZMhfGinIHnueIVve2m2eTDv[kB1cGViaHnnbIVzKG2xYnnsbZR6KEyDTWDzJIF1KHSqZTDjc5N1KG:oIITo[UBtd3encjDtc4JqdGm2eTDzdIVkcWW| NGC2PIUzPTR6OE[2Oi=>
SP-Nluc MU\GeY5kfGmxbjDBd5NigQ>? M4rudVUhdWdxbVy= MWi2JIg> NGLjTo9FVVORwrC= NVXFdI5J[2G3c3XzJIFvKGmwY4LlZZNmKGmwIILldI9zfGW{IHHjeIl3cXS7IHnuJJRp\SCyYYLhd4l1\Q>? NX7FXVFWOjV|OUK5PVg>
PEXEL-Nluc MVTGeY5kfGmxbjDBd5NigQ>? NX[2VlVmPSCvZz;tUC=> M33mflYhcA>? NVzkXo9KTE2VT9Mg M3HHNINifXOnczDhckBqdmO{ZXHz[UBqdiC{ZYDvdpRmeiCjY4Tpeol1gSCrbjD0bIUheGG{YYPpeIU> NXnjcJd[OjV|OUK5PVg>
H1299 MVHGeY5kfGmxbjDBd5NigQ>? NVHrZ4xSOTBizsznM41t NUXzTYpIOjRiaB?= NESxXVJqdmS3Y3XzJIF2fG:yaHHnfeKh NX3kRpdSOjV|OEi5O|A>
MDA-MB-231 NETWfXdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MUCw5qCUPTBizsznM41N NVHJeIgyPDhiaB?= MX3FR|UxyqB;IECuNFE3KML3Zz;tUC=> NFroSGgzPTN3NkW2Oy=>
MDA-MB-231 MXPBdI9xfG:|aYOgRZN{[Xl? M2HsZVAvOSEQvHevcWw> NWHrTpJNPCCq MlnObY5lfWOnczDhdI9xfG:|aYO= NVnDeVIzOjV|NU[1Olc>
MDA-MB-231 MlTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXSOVhGOC5yMT:wMlA2KM7:Zz;tUC=> MUiyOEBp NI\MPWdqdmO{ZXHz[ZMhfGinIH\yZYN1cW:wIH;mJJN2[i2JMTDj[YxtKGSnYoLpdy=> MlHFNlU{PTZ3Nke=
MDA-MB-231 NFztWWxCeG:ydH;zbZMhSXO|YYm= MljFNE4xPeLCk{Gg{txoN22O NIG1XIwzPCCq M1LIeolv\HWlZYOgVGFTWCBqcH;sfUBCTFBvcnnic5NmKHCxbInt[ZJie2VvMTmgZ4xm[X[jZ3W= MnnoNlU{PTZ3Nke=
MDA-MB-231 NVLDeVdzTnWwY4Tpc44hSXO|YYm= MXGw5qCUPTBizsznM41N MmC2NlQhcA>? MorzbY5pcWKrdIOgeIhmKG[xcn3heIlwdiCxZjCzSEBidmRiMlSgZ49td26rZYO= MmPONlU{PTZ3Nke=
A172 NFnSe4tHfW6ldHnvckBCe3OjeR?= MkXmNVDDqM7:Zz;tcC=> NIDweYw1yqCq MYXEUXNQyqB? MWDy[ZN2dHS|IHnuJJRp\SC{ZYTyc4dz[WSnIITyZY5{eG:{dDDv[kBndHWxcnXzZ4VvfCCpcnHueYxmew>? MnrhNlUzOzl3MEe=
KMS-6 MorGSpVv[3Srb36gRZN{[Xl? NHHZRooyyqEQvF5CpC=> M133NVI1KGh? NV7lU2Jq\XiqaXLpeJMhcGGuZjD0bIUhe2WlcnX0bY9vKG:oIHfhcIFvcW5vTFmgZZMh\GmmIITo[UBkd262cn;s M3\OfVI2OjJ7MUK2
MEC Mli4SpVv[3Srb36gRZN{[Xl? MkHRNUDPxE1? NYL3[mdWOS53IHi= MkOwZ4F2e2W|IHGg[JJidWG2aXOg[IVkemWjc3WgbY4hfGinIIP1doZi[2ViVlXHSnIz M4O2eVI2OjJ6OEG1
HEK293/hERG NE[5cGdHfW6ldHnvckBCe3OjeR?= M33VSlExyqEQvF2= MU[xxsBp NULXW2lEemW|dXz0d{BqdiCjIITpcYUu\GWyZX7k[Y51KHKnZIXjeIlwdiCvYYT1doUhcEWURzDwdo91\WmwwrC= NYPZWVFWOjV{MUi0Olk>
RBE4 NGXOS5FCeG:ydH;zbZMhSXO|YYm= NGHucVMzyqEQvF2= MkHXN-KBmzJ2wrDo MlvJbY5lfWOnczDhdI9xfG:|aYOgeIlu\SCmZYDlcoRmdnSueR?= MVqyOVEzQDB{NR?=
RBE4 NY\wT3ZuTnWwY4Tpc44hSXO|YYm= NHzabYwzyqEQvF2= M4j1U|PjiJN{NNMgbC=> MmfIbY5kemWjc3XzJJRp\SC[QmCxJJBzd3SnaX6gcIV3\Wy|IHHmeIVzKDNiYX7kJFbDqGhib3[geJJm[XSvZX70 M131U|I2OTJ6MEK1
RBE4 NFvxdYJHfW6ldHnvckBCe3OjeR?= MXyyxsDPxE1? MoXnN-KBmzJ2wrDo NUXk[IZzcW6lcnXhd4V{KGGldHn2[UBk[XOyYYPlMVEzKGmwIHGgeIlu\S2mZYDlcoRmdnRibXHucoVzyqB? NFTlVpMzPTF{OECyOS=>
RBE4 NHS0OZVHfW6ldHnvckBCe3OjeR?= MYqyxsDPxE1? NEPN[Gk{6oDVMkVCpIg> M2TqUolv[3KnYYPld{B1cGVibHX2[Yx{KG:oIGLPV{B1cW2nLXTldIVv\GWwdHz5 NVf5WFRtOjVzMkiwNlU>
RBE4 NV7ldIxGTnWwY4Tpc44hSXO|YYm= M{fIfFLDqM7:TR?= MXyz5qCUOjUEoHi= M17KcYlv\HWlZYOgZUBl\WyjeXXkJIRmeGyndHnvckBw\iC2aHWgSXIhS2F{K9MgZ49vfGWwdDDheEA3yqCqIH;mJIlv[3WkYYTpc44he2mpbnnmbYNidnSueR?= NGP2NWMzPTF{OECyOS=>
RBE4 MXrGeY5kfGmxbjDBd5NigQ>? NWTlbYdOOsLizszN MnPUN-KBmzJ2wrDo NXPnVINYcW6mdXPld{BidiCxdnXycI9i\CCxZjDDZVIsyqCrbjD0bIUhdWm2b3Poc45lemmjIHnuJJRp\SCoaYLzeEA3yqCqIH;mJIlv[3WkYYTpc44hMHEkgJm85qCKOC5yMEGpJIJ2fCCFYUKrxsBt\X[nbIOgbY4hfGirczDvdodidmWubHWg[IVkemWjc3XkJIFnfGW{IEGyxsBpKG:oIHnuZ5Vj[XSrb36= MlfTNlUyOjhyMkW=
Huh-7  NHPCbYxHfW6ldHnvckBCe3OjeR?= M4\zXlHPxGdxbVy= NHm0T2k{6oDVMkVCpIg> NELobodqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIFHQSVEhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> M3;JbFI2ODJ4MUe0
HepG2  MmniSpVv[3Srb36gRZN{[Xl? NHfYd5Yy|rypL33M M3:3WFPjiJN{NNMgbC=> MnPObY5kemWjc3XzJJRp\SCuZY\lcEBw\iCDUFWxJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXy NGPUZYYzPTB{NkG3OC=>
H838-LKB1 MVXGeY5kfGmxbjDBd5NigQ>? MlqxN|DDqG6pL33s NUn3[npMOTJxMUigbC=> MnqybY5kemWjc3XzJJRp\SCycn;0[YlvKGyndnXsd{Bw\iCEaWFCpC=> NH3ZUoIzPTBzMUC4Ni=>
H838-KDLKB1  NUKxSVZsTnWwY4Tpc44hSXO|YYm= NUfKTY9TOzEEoH7nM41t Mm\xNVIwOThiaB?= M3TVUYlv[3KnYYPld{B1cGVicILveIVqdiCuZY\lcJMhd2ZiQnnQxsA> Mom0NlUxOTFyOEK=
H838-KDLKB1  MWLGeY5kfGmxbjDBd5NigQ>? MmnWN|DDqG6pL33s MXOxNk8yQCCq MofTbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZicHjvd5Bpd3K7bHH0[YQh\UmIMt8xJEhxcG:|cHjvMYVKTjMQsTm= Mlr3NlUxOTFyOEK=
3T3-L1 M{XSfWZ2dmO2aX;uJGF{e2G7 M1XJclUh|rypL33s MlHON|AhdWmw M4rUdY1qdWmlczD0bIUh\W[oZXP0d{Bw\iCrboP1cIlvKGGwZDDjZZV{\XNicn;ieZN1KHCqb4PwbI9zgWyjdHnvckBw\iCDa4SgLHNmeiB2N{OpJIFv\CCyaH;zdIhwenmuYYTpc44hd2ZiQWOxOlAhMFSqcjC2OFIh[W6mIGPldkA2QDhr MkHpNlQ5PDN6Mke=
3T3-L1 NWizZnhqTnWwY4Tpc44hSXO|YYm= NVftOFQyPSEQvHevcYw> M{LTUVMxKG2rbh?= NWrCe2x7emWlYYDpeJVt[XSnczDpcpN2dGmwIHHjeIlwdiC5aYToJJJme3CnY4SgeI8hemWpdXzheIlv\yCDa4SgZYN1cX[rdImgZY5lKEGVMU[wJJBpd3OyaH;yfYxifGmxbh?= NUT2U|R3OjR6NEO4Nlc>
3T3-L1 MXrGeY5kfGmxbjDBd5NigQ>? NUnQZoFsPSEQvHevcYw> NXnRdpVKOzBibXnu MlGyZ4F2e2W|IILleoVze2mkbHWgdoVlcXO2cnnieZRqd25ib3[gS2xWXDR? NILpS5AzPDh2M{iyOy=>
3T3-L1 MVLGeY5kfGmxbjDBd5NigQ>? MkTMOUDPxGdxbXy= NV\qfnFROcLiaB?= MX\jZZV{\XNicnXkbZN1emmkdYTpc44hd2ZiR1zVWFQh[nW2IH7veEBqdmO{ZXHz[UBqdiCpbIXjc5NmKHWydHHr[S=> MXSyOFg1Ozh{Nx?=
3T3-L1 NWDHWnZiTnWwY4Tpc44hSXO|YYm= NVm5XGZHPSEQvHevcYw> NFX4OGQyyqCq NVr1OpNE[2G3c3XzJJBpd3OyaH;yfYxifGmxbjDv[kB1cGViRn;4U|EhfHKjboPjdolxfGmxbjDmZYN1d3J? MoqzNlQ5PDN6Mke=
HeLa  NHfNV|ZHfW6ldHnvckBCe3OjeR?= MUm1JO69\y:vbB?= MUWzJIg> NHG4[IZk[XW|ZYOgcpVkdGWjcjDlfINtfXOrb36gc4YhfGinIF\vfG8yKHS{YX7zZ5JqeHSrb36g[oFkfG:{IHHu[EBl\WO{ZXHz[ZMhfHKjboPjdolxfGmxbjDv[kBHd3iRMT3y[Yd2dGG2ZXSg[4Vv\XN? M1vMRlI1QDR|OEK3
HEK293 M2X4bWZ2dmO2aX;uJGF{e2G7 NV7sTmxpPcLizsznM41t MV6xNuKhcA>? NYHxNY1W[WKxbHnzbIV{KEOPQT3pcoR2[2WmIFPSSWxFOiC|ZXPy[ZRqd25? MXmyOFY5PzR|MR?=
COS-1 MW\GeY5kfGmxbjDBd5NigQ>? M1PM[FUhyrWpL33s NEOzbFMzPCCqwrC= MlfwdoV{fHKrY4TzJIxw[2GuaYrheIlwdiCxZjDORkBqdiC2aHWgdIVzcW63Y3zlZZIhemWpaX;uxsA> NFn6bIEzPDZ5MUe1NS=>
PRP Mmn1SpVv[3Srb36gRZN{[Xl? MYKxNEDPxE1? MmjTZYJzd2ejdHXzJHNFTi1zzsGtcYVlcWG2ZXSgR3hEWjdiZYj0[ZJv[WyrenH0bY9vyqB? MoruNlQ3Pjh5NUC=
RAW264.7 MmWzRZBweHSxc3nzJGF{e2G7 M{fZclQh|ryP NGXibG01QCCq NEXFW2pifHSnboXheIV{KHSqZTDpcohq[mm2aX;uJI9nKG:6LVzEUE1qdmS3Y3XkJIFxd3C2b4Ppd{BidmRidHjlJIZi[2muaYTheIlwdiCxZjDjbI9t\XO2ZYLvcEBm\m[udYigZpkhSWNvaFWtNVhCNU6KMh?= NITJXnMzPDZ|OUCzNi=>
MDMs NID0fY9CeG:ydH;zbZMhSXO|YYm= MW[xNQKBkc7:Zz;tcC=> M{HUO|EzNzF3IHi= NF;QeFRqdmS3Y3XzJIFxd3C2b4Ppdy=> MoDTNlQ2PTZ4OUW=
PMHs  M{K1[GZ2dmO2aX;uJGF{e2G7 NVLIW49OOTEkgKOyNQKBkc7:Zz;tcC=> MY[yOQKBkWh? Mmi4SG1UVw>? NI\qfm1qdmS3Y3XkJGVTKHO2cnXzdy=> NX3w[Y16OjR2MEeyOFI>
PMHs  M1nLbGFxd3C2b4Ppd{BCe3OjeR?= MUGxNQKBmzJy4pEJ{txoN22u M1;p[lI16oDLaB?= MnzaSG1UVw>? MnvObY5kemWjc3XzJINmdGxiZHXheIg> MYeyOFQxPzJ2Mh?=
HEK293/tau M2qzd2Z2dmO2aX;uJGF{e2G7 M{nZcFUh|ryP M3rZPFEwOi92IHi= NV\CVZJPcW6mdXPld{BId2ypaTDmdoFodWWwdHH0bY9vyqB? NHnI[3YzPDN4OEC4PS=>
HEK293/tau NF3pPJpHfW6ldHnvckBCe3OjeR?= MV[1JO69VQ>? MUKzJIg> M1LtdIlv\HWlZYOgeIF2KGi7cHXydIhwe3Cqb4L5cIF1cW:w NGLHb|YzPDN4OEC4PS=>
ADF MkTKSpVv[3Srb36gRZN{[Xl? NXLxR|hrOTBizszN MkWwNVYhcA>? MWfpcohq[mm2czD0bIUhYm6FbEKtbY5lfWOnZDD0doFve2yxY3H0bY9vKG:oIFPSWC=> Mn;xNlQzOjh{M{K=
U373  MXrGeY5kfGmxbjDBd5NigQ>? M3fWS|ExKM7:TR?= NUTHRZhlOTZiaB?= NUSyR241cW6qaXLpeJMhfGinIGruR4wzNWmwZIXj[YQhfHKjboPsc4NifGmxbjDv[kBEWlR? NGDpd4szPDJ{OEKzNi=>
RKO-HIPK2i M1\OV2Z2dmO2aX;uJGF{e2G7 MVmxNEDPxE1? NXjoVnJ4OTZiaB?= MUXpcohq[mm2czD0bIUhYm6FbEKtbY5lfWOnZDD0doFve2yxY3H0bY9vKG:oIFPSWC=> NGLlcGwzPDJ{OEKzNi=>
ADF  NYnU[od[TnWwY4Tpc44hSXO|YYm= MmrQNVAh|ryPwrC= NFz0SXk3KGh? NUTESJAxcW2yYXnyd{B1cGViRFOgZYN1cX[jdHnvci=> MYeyOFIzQDJ|Mh?=
Huh7 NUDufZJ1TnWwY4Tpc44hSXO|YYm= NVuyd4w2PSEQvHevcYw> MX[0JIg> MVzhZo9tcXOqZYOgeIhmKHOnY4LleIlwdiCxZjCgbY51emGlZXzseYxieiCDcH;C M1v1TlI1OTByMUSw
Huh7 MmTxSpVv[3Srb36gRZN{[Xl? MnrUOUDPxGdxbXy= MnHqNUBp NH;hU|dk[XW|ZYOgZUB{cWewaX\pZ4FvfCCrbnPy[YF{\SCrbjDBdI9DNWO{ZYPj[Y51ew>? NFfP[JozPDFyMEG0NC=>
Huh7 NV;yNGwyTnWwY4Tpc44hSXO|YYm= MoXhOgKBmzFywrDu[{9udA>? M{DvfVEzKGh? MnTvbY5kemWjc3XzJGFxd0JvY4Lld4NmdnS|IIfpeIhwfXRiaX7obYJqfGmwZzDz[YNz\XSrb36= NH\Fb4EzPDFyMEG0NC=>
BAECs M{XF[WZ2dmO2aX;uJGF{e2G7 Mlq5OUDPxGdxbXy= NInrcIYxNTRiaB?= M3HjZolv\HWlZYOgeIhmKHKjcHnkJIRmeGixc4Doc5J6dGG2aX;uJI9nKGWQT2OgZZQhW2W{MUG3PS=> M3HFXlI1ODh3MkK1
Macrophages NWSyZnVuTnWwY4Tpc44hSXO|YYm= NHHFOJM4OSEEtV2= MoDhOkBp MVnpcohq[mm2czDseY5ie2mwIHnueIVzdmGuaYrheIlwdsLi MXKyOFA{QTd2MB?=
Colo 205 M1X5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mln1NE02KM7:Zz;tUC=> M4TqOVQ5KGh? NVztXGFQcW6qaXLpeJMh[2WubDDndo94fGhiaX6gd5V{eGWwc3nvckBkfWy2dYLld{B4cXSqIHHuJIV{fGmvYYTl[EBKSzVyIH;mJJ4yPSCwZz;tUC=> NIraVHAzOzl5M{m5Oi=>
Colo 205 M3m2RWZ2dmO2aX;uJGF{e2G7 MVSwMlAyOi1yLkCyOUDPxGdxbVy= M3[4WFE1KGR? MkfHdoVlfWOnczD0bIUh[2yxbn;n[Y5q[2m2eTDv[kBEd2yxIEKwOUBEW0O| M2q0OFI{QTd|OUm2
Colo 205 NECwbZRCeG:ydH;zbZMhSXO|YYm= MkWzNE4yKM7:Zz;tUC=> Mm[2NE0zPCCq MkP6bY5lfWOnczDhdI9xfG:|aYOgc4YhS2:ubzCyNFUh[2WubIOgbY4he3W|cHXud4lwdiCldXz0eZJmew>? MoTINlM6PzN7OU[=
Colo 205 NVSxTnI4TnWwY4Tpc44hSXO|YYm= M{j2NlAvODF3IN88[{9uVA>? M1XkclI1KGh? NYnwZ5dScW6mdXPld{B1cGViZYjwdoV{e2mxbjDv[kBGWiC|dILld5MuemWuYYTl[EBo\W6ncx?= Mk\rNlM6PzN7OU[=
Colo 205 M3njPGZ2dmO2aX;uJGF{e2G7 M2q1SlAvODF3IN88[{9uVA>? MmLpNlQhcA>? M{GzfolvcGmkaYTzJJRp\SCjY4Tpeol1gSCxZjDNUXB{ NEjjdJEzOzl5M{m5Oi=>
IBRS2 MUjGeY5kfGmxbjDBd5NigQ>? M3PvRVUh|rypL33s MWmwMlUhcA>? MnzXSG1UVw>? Ml\H[Il{enWydIOgeIhmKEWUR1nDJIFv\CCJb3znbeKh NWnYR5FFOjN7NkO1N|Q>
IBRS2 M1XiWmZ2dmO2aX;uJGF{e2G7 M{HUc|Uh|rypL33s MWCwMlUhcA>? NVrEWoVyTE2VTx?= MojW[Y5p[W6lZYOgSm1FXiCrbn\lZ5Rqd25? M3X5VFI{QTZ|NUO0
HeLa MmnWSpVv[3Srb36gRZN{[Xl? MYSyJO69VQ>? NYHCc3pJOiCqwrC= M{flZ4F1fGWwdXH0[ZMhfGinIGTOSk1qdmS3Y3XkJJNm[3KndHnvckBw\iCLTD2xOS=> MoThNlM6PTB6OUK=
HFS  MXfGeY5kfGmxbjDBd5NigQ>? MV2wMVEh|rypL33s NEHIbIgzPCCq M2K3cmdNXFBiZYjwdoV{e2mxbjDy[YFkcGW|IHGgdIxifGWjdTDheEBkd26lZX70doF1cW:wczDhd{Btd3diYYOgNE4xOSEEtXevcYw> MkK4NlM5QTR4M{O=
HFS  MYTGeY5kfGmxbjDBd5NigQ>? MV2wMlAyKML3Zz;tcC=> MYiyOEBp NWnieXVncW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKGeueXPvd5BpcW6pb3zpdIllKHO7boToZZNmKGenbnXzJIF1KDZiaB?= MWqyN|g6PDZ|Mx?=
OVCAR-3 Ml;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPvZW5VOeLCk{G1xsDPxE4EoB?= NUPxdWhNOjUEoHi= MnexbY5lfWOnczDhJIxwe3Nib3[gZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgcLi M{fz[|I{QDJ4OU[0
OVCAR-3 M4rYfWZ2dmO2aX;uJGF{e2G7 NHr5WWEy6oDVMUZCpO69VcLi NUnPPWtMOjUEoHi= NXnqfJpmcW6mdXPld{BvfWOuZXHyJIRidWGpZR?= NEXiUYczOzh{Nkm2OC=>
OVCAR-3 M3HqW2Fxd3C2b4Ppd{BCe3OjeR?= NYXqcGt5OS1zMNMg{txO NFXTT3U1KGh? NVrhXnptcW6mdXPld{B1cGViYXP0bZZifGmxbjDv[kBieG:ydH;zbZMuemWuYYTl[EBxem:2ZXnudy=> NXrqVItROjN6Mk[5OlQ>
OVCAR-3 Mmj3RZBweHSxc3nzJGF{e2G7 NGnVfmoyOMLizszN NIXiVHczPMLiaB?= NYfMfG5WcW6mdXPld{Bi[3SrdnH0bY9vKG:oIHPhd5Bie2W| MUOyN|gzPjl4NB?=
OVCAR-3 MX7GeY5kfGmxbjDBd5NigQ>? MYOx5qCUOTEEoN88US=> NEf2foIzPMLiaB?= MXzpcoR2[2W|IHTpd5J2eHSrb36gc4YhfGinIH3peI9kcG:wZILpZYwhfHKjboPt[Y1jemGwZTDwc5RmdnSrYXy= NUnkXmluOjN6Mk[5OlQ>
OVCAR-3 NUX0UYo4TnWwY4Tpc44hSXO|YYm= MXix5qCUOTEEoN88US=> NEizXGUzPMLiaB?= M1ewNolv\HWlZYOg[o9zdWG2aX;uJI9nKHKnYXP0bZZmKG:6eXflckB{eGWlaXXz NWj5[WJUOjN6Mk[5OlQ>
OVCAR-3 MYDGeY5kfGmxbjDBd5NigQ>? M1fMWVHjiJNzMNMg{txO M3PIflI1yqCq NVXvboFTcW6qaXLpeJMh[2WubDDh[Ihme2mxbjDhcoQhdWmpcnH0bY9v MVKyN|gzPjl4NB?=
MKN45 MnOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\0fldKSzVyPECuNFAyKM7:Zz;tcC=> NWi2S4NoOjN5OUOzOFI>
LOVO NYDOZZc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWq4cXBVUUN3ME2wMlEzKM7:Zz;tcC=> M3XDOFI{Pzl|M{Sy
A549 NXHMeJVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3hTWM2OD1yLkC0JO69\y:vbB?= MX2yN|c6OzN2Mh?=
MDA-MB-435 NEPmflZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LmTGlEPTB:MD6wNFEh|rypL33s NXjuNY5yOjN5OUOzOFI>
HepG2 MlnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnqU|dMUUN3MEywMlAxOSEQvHevcYw> NGHt[FQzOzd7M{O0Ni=>
HL-60 NVTPRpZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGmxcXBKSzVyPECuNFAyKM7:Zz;tcC=> MmfBNlM4QTN|NEK=

... Click to View More Cell Line Experimental Data

Protocol

Cell Research:[5]
+ Expand
  • Cell lines: Human follicular lymphoma cell lines HF1A3, HF4.9 and HF28RA
  • Concentrations: 0 ng/mL -75 ng/mL
  • Incubation Time: 5 days
  • Method: HF1A3, HF4.9 cell viability upon the treatments is tested using double staining of cells with YO-PRO 1/PI and SYTO16/PI probes. To access cell proliferation, cells are treated with 0–100 ng/mL Brefeldin A in complete medium for 20 hours before adding 1 μCi/mL [methyl-3H]-thymidine for additional 4 hours at 37 °C. The incorporated radioactive thymidine is quantified by scintillation counting with Microbeta counter. To examine long-term effects of Brefeldin A treatment, cells are seeded at initial concentration 105 cells/mL and treated with 0-75 ng/mL Brefeldin A for up to 5 days. At the time indicated, a sample of cells is removed and viable cell number is assessed by standard Trypan Blue exclusion assay.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (14.26 mM)
Water <1 mg/mL
Ethanol <1 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 280.36
Formula

C16H24O4

CAS No. 20350-15-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATPase Signaling Pathway Map

Related ATPase Products

Tags: buy Brefeldin A | Brefeldin A supplier | purchase Brefeldin A | Brefeldin A cost | Brefeldin A manufacturer | order Brefeldin A | Brefeldin A distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID